Skip to content
BiologicalX

Comparison

Hexarelin vs Modafinil

Side-by-side of Hexarelin and Modafinil. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

Effects at a glance

Hexarelin

  • Synthetic hexapeptide GHS-R1a agonist; produces the largest acute GH pulse of the synthetic GHRP class
  • Independent CD36 signaling produces cardioprotective effects in rodent ischemia models, GH-independent
  • Pronounced tachyphylaxis: GH response attenuates over 2 to 4 weeks of daily dosing
  • More cortisol and prolactin elevation than GHRP-2 or ipamorelin
  • Anecdotal protocols use 100 to 200 mcg subcutaneously 1 to 2 times daily for 2 to 4 week pulses
  • Banned by WADA under S2; advanced through phase 2 trials but never reached registration

Modafinil

  • FDA approved in 1998 for narcolepsy, with later additions for shift-work sleep disorder and OSA residual sleepiness
  • Schedule IV controlled substance in the US; prescription-only in EU, UK, Australia
  • Increases wakefulness via weak dopamine reuptake inhibition plus histaminergic, noradrenergic, and orexinergic activation
  • Long half-life of 12 to 15 hours requires morning dosing to avoid sleep disruption
  • Modest cognitive enhancement signal in non-sleep-deprived adults at 100 to 200 mg (Battleday meta-review 2015)
  • Substantial CYP3A4 induction reduces hormonal contraceptive efficacy; barrier methods recommended

Side-by-side

Attribute Hexarelin Modafinil
Category peptide pharmaceutical
Also known as Examorelin, EP-23905, His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2 Provigil, Modalert, Modvigil, diphenylmethylsulfinyl-acetamide
Half-life (hr) 1 13
Typical dose (mg) 0.1 200
Dosing frequency 1-2x daily daily, morning
Routes subcutaneous, intranasal, intravenous oral
Onset (hr) 0.25 1
Peak (hr) 0.5 3
Molecular weight 887.04 273.35
Molecular formula C47H58N12O6 C15H15NO2S
Mechanism Hexapeptide agonist of GHS-R1a producing acute GH release with cortisol and prolactin co-elevation. Independent CD36 binding produces GH-independent cardioprotective signaling in preclinical models. Weak dopamine reuptake inhibition plus downstream activation of histaminergic, noradrenergic, and orexinergic wake-promoting systems.
Legal status Not FDA approved; advanced through phase 2 trials in EU but never registered; research-use-only grey market; banned by WADA Schedule IV (US); prescription-only globally; not a supplement
WADA status banned banned
DEA / Rx Not scheduled (research chemical) Schedule IV
Pregnancy Insufficient data; not recommended Not recommended
CAS 140703-51-1 68693-11-8
PubChem CID 3037387 4236
Wikidata Q5743550 Q422968

Safety profile

Hexarelin

Common side effects

  • water retention
  • vivid dreams
  • head pressure or flushing
  • transient lethargy
  • tingling at injection site
  • moderate hunger

Contraindications

  • pregnancy
  • active malignancy
  • history of pituitary tumor
  • uncontrolled diabetes
  • prolactin-sensitive states

Interactions

  • CJC-1295: synergistic GH release; accelerates tachyphylaxis if used continuously(minor)
  • sermorelin: additive GH release via parallel GHRH and ghrelin pathways(minor)
  • insulin: sustained GH can blunt insulin sensitivity over weeks(moderate)
  • corticosteroids: amplify cortisol load; blunt GH response(moderate)

Modafinil

Common side effects

  • headache
  • nausea
  • anxiety
  • insomnia (with late-day dosing)
  • dry mouth
  • mild blood pressure elevation

Contraindications

  • recent myocardial infarction
  • unstable angina
  • left ventricular hypertrophy
  • significant arrhythmia
  • history of Stevens-Johnson syndrome
  • psychotic disorders
  • pregnancy
  • concurrent MAOI use

Interactions

  • hormonal contraceptives: CYP3A4 induction reduces contraceptive efficacy; use barrier method(major)
  • cyclosporine: reduced cyclosporine levels via CYP3A4 induction(major)
  • warfarin: CYP2C9 inhibition raises INR(moderate)
  • phenytoin: CYP2C19 inhibition raises phenytoin levels(moderate)
  • MAOIs: potential hypertensive reaction(major)
  • classical stimulants (amphetamine, methylphenidate): additive cardiovascular and sleep-disruption effects(moderate)

Which Should You Take?

Modafinil comes out ahead for most readers on the criteria we weight: 3 catalogued goals, controlled substance, oral dosing, with a Tier-A outcome catalogued. Hexarelin is the right call when one of the conditionals below applies.

  • If your priority is growth-hormone axis, pick Hexarelin.
  • If your priority is post-training recovery, pick Hexarelin.
  • If your priority is wakefulness, pick Modafinil.
  • If your priority is focus or working memory, pick Modafinil.

Edge case: If you cannot self-administer injections, Modafinil is the only oral option in this pair.

Default choice: Modafinil. Wider use case, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Hexarelin only if your priority sits squarely in the goals it owns above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between Hexarelin and Modafinil?

Hexarelin and Modafinil differ in category (peptide vs pharmaceutical), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, Hexarelin or Modafinil?

Hexarelin half-life is 1 hours; Modafinil half-life is 13 hours.

Can you stack Hexarelin with Modafinil?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper